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Evidence Synthesis for Decision Making 1:
Introduction
Sofia Dias, PhD, Nicky J. Welton, PhD, Alex J. Sutton, PhD, A. E. Ades, PhD
We introduce the series of 7 tutorial papers on evidence
synthesis methods for decision making, based on the
Technical Support Documents in Evidence Synthesis pre-
pared for the National Institute for Health and Clinical
Excellence (NICE) Decision Support Unit. Although
oriented to NICE’s Technology Appraisal process, which
examines new pharmaceutical products in a cost-
effectiveness framework, the methods presented through-
out the tutorials are equally relevant to clinical guideline
development and to comparisons between medical devi-
ces, or public health interventions. Detailed guidance is
given on how to use the other tutorials in the series, which
propose a single evidence synthesis framework that covers
fixed and random effects models, pairwise meta-analysis,
indirect comparisons, and network meta-analysis, and
where outcomes expressed in several different reporting
formats can be analyzed without recourse to normal ap-
proximations. We describe the principles of evidence syn-
thesis required by the 2008 revision of the NICE Guide to
the Methods of Technology Appraisal and explain how
the approach proposed in these tutorials was designed
to conform to those requirements. We finish with some
suggestions on how to present the evidence, the synthesis
methods, and the results. Key words: cost-effectiveness
analysis; Bayesian meta-analysis; systematic reviews.
(Med Decis Making 2013;33:597–606)
This paper is the first of 7 tutorial papers on evi-dence synthesis methods in decision making,
which are based on the Technical Support Docu-
ments (TSDs) in Evidence Synthesis prepared for
the National Institute for Health and Clinical Excel-
lence (NICE) Decision Support Unit and available
from http://www.nicedsu.org.uk/. The TSDs are in-
tended to support the appraisals process, which ex-
amines new pharmaceutical products in a cost-
effectiveness framework,1,2 by explaining the re-
quirements in the 2008 revision of the NICE Guide
to the Methods of Technology Appraisal,3 by show-
ing how analyses can be implemented so that they
have the required properties, and by giving concrete,
worked examples. Although aimed at those making,
reviewing, and appraising submissions to NICE, the
TSDs do not attempt to ‘‘prescribe’’ the form that
analyses must take or the methods that must be
used. Any methods fulfilling the required properties
are valid. It should be noted that the 2008 methods
guide will shortly be replaced by the 2013 revision,
currently only available as a draft for consultation.
The main changes in this draft, which have been
largely anticipated by the TSDs, relate to trial inclu-
sion criteria and presentation of the evidence and
results.4
This series of tutorial papers is intended primarily
to introduce the proposed Bayesian evidence synthe-
sis methods to a wider audience and to address evi-
dence synthesis issues concerning the relative and
absolute efficacy of interventions. In this introduc-
tory paper, we suggest how to use the tutorial series
in practice, set out the key properties of evidence syn-
thesis for decision making in NICE Technical
Appraisals, and explain the reasons why the pro-
posed approach is particularly suited to this context.
We finish with some suggestions on how to present
the evidence, the synthesis methods, and the results.
The methods used in NICE Technical Appraisals
have tended to set a benchmark for methods used in
other work that NICE undertakes. For example, the
methods advocated in the 2008 Guide to Methods of
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Technology Appraisal are referred to in NICE’s 2009
Clinical Guidelines Manual,5 and the 2012 update6
refers directly to TSDs on which this tutorial series
is based. Thus, the methods proposed are equally rel-
evant to clinical guideline development and to com-
parisons between medical devices or public health
interventions. The series does not, however, cover
questions arising from the synthesis of data on diag-
nostic test performance7 or general synthesis of epi-
demiological data,8 largely because issues in
diagnostic technologies, screening, and public health
are outside the remit of the NICE appraisals process.
USING THE TUTORIAL SERIES
The tutorial series can be used as a learning tool for
anyonewishing to carry out evidence synthesis in the
context of decision making, whether on clinical
grounds or for cost-effectiveness. The methods can
clearly be extended further into comparisons that
set benefits against side effects and analyses based
on multicriteria decision analysis.9
The second tutorial in this series10 sets out the pro-
posedBayesian framework andprovides an extensive
appendix with WinBUGS code for the core pairwise
and Network Meta-analysis (NMA) model, with
worked examples for various types of outcomes.
This includes details of how to set up data, obtain
key outputs, and present and interpret the results.
Because of themodular nature of the code, once read-
ers are familiar with the core NMA model for bino-
mial data and how it needs to be changed for other
data types, they will be able to adapt the code in the
remaining tutorials (e.g., for meta-regression11 or
inconsistency checking12) to suit their own data.
Table 1 sets out the examples and data sets presented
in the other tutorials in this series and summarizes
what can be learned from studying them. However,
before one attempts the Bayesian evidence syntheses
proposed, a thorough grounding in Bayesian statis-
tics and the use of WinBUGS13 is required. The Win-
BUGS manual14 and its online tutorial, particularly
the ‘‘Blocker’’ example in the Help menu, as well as
many other examples available elsewhere,15,16 are
key resources, as is an introduction to Bayesianmeth-
ods.16,17 Proper attention to the technical aspects of
WinBUGS, such as convergence and burn-in, is
essential.
Having completed these preliminaries, readers
will be ready to start analyzing their own data set.
We strongly recommend starting with the simplest
analysis, a pairwise meta-analysis, before attempting
an NMA, using the code provided.10 Once this has
been mastered, one can step up to NMA and then to
shared parameter models.10 The methods for meta-
regression including bias adjustment and inconsis-
tency checking, described in the third11 and fourth12
tutorials in this series, can be attempted next, but at
each stage it is essential that readers monitor all rele-
vant parameters (nodes) and make sure they under-
stand every aspect of the outputs and procedures
for checking convergence before moving on to the
next stage.
Readers interested in evidence synthesis for
the baseline natural history model and in using
the results of the synthesis in a probabilistic cost-
effectiveness analysis (CEA) should also consult the
fifth and sixth tutorials in this series.18,19
All readers, whether experienced or not, may ben-
efit from the checklist,20 as this sets out what journal
reviewers and the general reader are likely to
question.
EVIDENCE SYNTHESIS IN NICE’S GUIDE TO THE
METHODS OF TECHNOLOGY APPRAISAL
Principles of Evidence-Based Decision Making and
Distributive Justice
The 2008 methods guide, like all other documents
and procedures at NICE, follows a set of basic princi-
ples. Some of these are derived from the legislation
governing NICE’s establishment, others from one of
its key foundational documents concerning social
value judgments.21 This sets out the principles of
evidence-based decision making and directs that
NICE must consider the ‘‘broad balance of clinical
benefits and costs.’’ It also spells out principles of dis-
tributive justice. What emerges from these basic prin-
ciples is a need to allocate scarce resources fairly, in
a way that gives patients ‘‘equal access’’ to care,
regardless of whether they have cancer, arthritis, or
any other condition. This, in turn, leads to CEA based
on optimizing expected net benefit, seen as mone-
tized health gain minus cost.
The emphasis on consistency of approach, both
across conditions and across appraisals, has implica-
tions for evidence synthesis, which we have inter-
preted as a requirement for a uniform approach to
synthesis, that can be applied to trials in any area of
medicine. This underlies our adoption of a general-
ized linear modeling (GLM) framework,10 with a uni-
form set of criteria for model fit, model selection, and
model diagnostics,10-12 regardless of the type of
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outcome (continuous, rate, proportion, etc.) that is
recorded and reported. It also leads to ‘‘shared param-
eter models,’’10 because the synthesis method and
results should not be affected by a trial’s reporting for-
mat. For example, one should be able to derive the
same estimates whether trials report mean treatment
differences or arm-based summaries, or whether
events and time at risk or numbers of patients reach-
ing end points are reported. Similarly, and for the
same reason, it leads us to more complex models for
synthesis of multiple outcomes10,19 that may be
reported differently in different trials.
Transparency
The social value document21 also emphasizes pro-
cedural justice: Recommendations must be based on
a transparent process, one that is open to challenge
and revision. Related to this, NICE follows a principle
of ‘‘inclusiveness’’: different stakeholders, whether
manufacturers, patients, or health care professionals,
must all have an opportunity to comment on the
scope of the recommendations and to challenge
them. Comments must be responded to, and there
are provisions for appeal. Although courts have not
challenged the appraisal committee’s scientific rea-
soning or its decisions, they have intervened to insist
that the basis for the decisions be fully explained.
This degree of accountability and transparency, as
well as the need for consistency between appraisals,
has led us to advocate a relatively limited set of
modeling options,10,11,18 some criteria for choosing
between them,10 and liberal use of sensitivity analy-
sis when there are insufficient grounds for choosing
one option over another.20 Although there is nothing
to prevent those making submissions to NICE from
using other methods if this can be reasonably justi-
fied, the fact that the apparatus for choosing one
model over another can be made uniform across dif-
ferent types of data and models10 is an essential pre-
requisite to meet requirements of transparency and
consistency.
Role of Indirect Comparisons and Network
Meta-analysis
The 2008 methods guide sets out the role of indi-
rect comparisons and NMA in a somewhat discon-
nected, but consistent, way. The main principle is
that ‘‘direct’’ evidence is strongly preferred, which
means that the NICE ‘‘reference case’’ or default anal-
ysis should be based only on trials directly comparing
the new treatments with standard comparators. Then
analyses based on indirect evidence, or combined
direct and indirect evidence (i.e., mixed treatment
comparison or NMA), can be presented as an addi-
tional analysis.
In practice, it is well recognized that this advice
can only be precisely applied where the decision fac-
ing the Appraisals Committee is between just 2 treat-
ments. As soon as there are 3 or more treatments in
the same decision problem, a method is required
that constructs a coherent set of comparisons based
onall the available trial evidence, rulingout a reliance
on purely ‘‘direct’’ comparisons in modeling (unless
all trials have arms for all the relevant treatments).
This is precisely what NMA models are designed to
achieve.
Relation between Pairwise and Network
Meta-analysis
NICE has 2 appraisal processes, multiple- and
single-technology appraisal (MTA, STA). In an
MTA, a set of competing new products are compared
with each other and with standard comparators,
whereas in an STA a single new product is under
scrutiny. Although an NMA is almost always used
in MTAs, STAs may be based on pairwise synthesis
or NMA. However, the methods guide requires that
themethods of assessment be the same. The evidence
synthesis models and the WinBUGS software for
implementing them presented throughout this
tutorial series10,11 have precisely this property: The
software will run either type of analysis without dis-
tinction, and the pairwise model is simply a special
case of the NMA model in which only 2 treatments
are being compared. This is not necessarily the case
in other models, or software, for NMA. The Lumley
model22 for NMA cannot be run on pairwise meta-
analysis or on indirect comparisons, nor in its pub-
lished formcan it deal correctlywith trials comparing
more than 2 treatments. These are serious shortcom-
ings, as manufacturers, clinicians, and decision mak-
ers will want to be assured that there is a single, fair
way of estimating treatment effects, regardless of
the structure of the evidence.
Trial Inclusion and Exclusion Criteria in
Construction of the Comparison Network
The 2008 methods guide explicitly allows submis-
sions to present indirect treatment comparisons that
include treatments that are not part of the decision
problem, if their inclusion makes a ‘‘connected’’ net-
work of randomized trials. Beyond that, however,
DIAS AND OTHERS
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little guidance is given on the size of a network or its
construction. A connected network is one in which
a direct or indirect comparison can be made between
every treatment, based on randomized data, therefore
allowing relative effects of every treatment relative to
every other to be estimated (Figure 1). The draft of the
2013 revision to the methods guide4 suggests the fol-
lowing simple rules for network construction. First,
in Figure 2a, three treatments A, B, and C are of inter-
est but an additional treatment X has been included
because there are trials comparing A v. X and C v. X,
thus forming a connected network. If treatments
could also have been connected by the addition of
A v. Y and C v. Y trials, then both X and Y should
be added to the comparator set (Figure 2b). Next,
every trial on the target population involving 2 or
more members of the comparator set should be
included. These rules are in the spirit of the prefer-
ence for direct evidence and both limit the network
to a minimum and identify a unique set of trials.
However, this means that trial searching and treat-
ment inclusion decisions may become an iterative
process when the initial treatment network is not
connected.
Bias in Randomized and Nonrandomized Evidence
The 2008 methods guide recognizes that random-
ized evidence is subject to potential biases regarding
its internal and external validity and that non-
randomized evidence, which may be needed if trial
evidence is weak, is even more vulnerable to these
problems.At the same time it calls for all the available
evidence to be integrated. This opens the possibility
of various approaches to bias and covariate adjust-
ment as part of the synthesis, which are described
in the third tutorial in this series.11
Modeling Natural History and Relative Treatment
Effects
The 2008 methods guide envisages a ‘‘baseline’’
model that represents the patient’s natural history
and care pathway on a standard treatment (e.g., usual
care or placebo), to which relative treatment effects
based on randomized evidence will be applied. It is
envisaged that the natural history model will often
be based on nonrandomized evidence and that there
will be a need to extrapolate beyond the trial out-
comes, as the default NICE base-case model requires
lifetime benefits and costs. This kind of modeling
approach, and relevant forms of synthesis, are
described in the fifth tutorial in this series.18
Subgroups and Meta-regression
Both effectiveness and cost-effectiveness of treat-
ments can differ by patient subgroup, and this may
occur because of differences in natural history or
because of differences in relative treatment effects.
Models based on differences in relative treatment
effects11 are permitted by the methods guide but
need to be supported by a priori biological plausibil-
ity and statistical evidence for interactions and must
be safeguarded against data dredging. Post hoc iden-
tification of subgroups is not precluded, but identifi-
cation at the scoping stage is preferred. Individual
participant data (IPD) are preferred for estimation of
subgroup effects, and we describe meta-regression
methods that can be used with aggregate data, indi-
vidual data, or a combination of both.11
Any proposed subgroup differences in general nat-
ural history require full documentation and justifica-
tion although they present no additional synthesis or
modeling challenges. However, NICE’s obligations
under human rights, discrimination, and equality
legislation prevent it from issuing guidance that
denies patients access to treatments on the basis of
A
C
B
X
(a)
A
C
B
X
Y
(b)
Figure 2 Treatment network in which the treatments relevant for
the decision and for synthesis differ. Lines represent a comparison
of the connected treatments in at least one trial. Treatments rele-
vant to the decision are in bold. (a) Treatment X has been added
to the synthesis because it links treatment C to the rest of the net-
work (dashed lines); (b) Treatment Y also links treatment C to the
network and needs to be added to the synthesis (long-dashed
lines).
A
C
B
X Y
Figure 1 Disconnected treatment network. Lines represent a com-
parison of the connected treatments in at least one trial. The net-
work formed by treatments A, B, and C is not connected to the
network formed by treatments X and Y.
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age, gender, race, disability, socioeconomic status, or
geographical location, except where these factors
directly affect the efficacy of treatment. This rules
out, for example, approval of a treatment in 65-year-
olds but not in 75-year-olds just because the expected
health gain is less in the latter group.
Uncertainty: Analytic Methods Compatible with
Probabilistic Cost-Effectiveness Analysis
It is essential that evidence synthesis methods are
fully compatible with the probabilistic CEA, as this is
the NICE reference case. The methods guide empha-
sizes the need for correctly propagating parameter
uncertainty and parameter correlation structure
through todecisionuncertainty, as the latter is amajor
consideration in appraisal committee decisions. The
syntheses methods proposed throughout this series
of papers, based on Bayesian posterior simulation
from joint parameter distributions, are specifically
designed tomeet these requirements. However, other
methods that also meet the requirements, at least
under some circumstances, are described in the sixth
paper in this series.19
Sensitivity Analysis
Throughout the methods guide there is an empha-
sis on the use of sensitivity analyses in the presence
of structural uncertainties of different types. Of par-
ticular relevance in evidence synthesis are the inclu-
sion or exclusion of specific trials in an evidence
network; the choice between fixed and random
effects models, especially when this cannot be
decided on the basis of goodness of fit; and the choice
between models with and without various adjust-
ments. Suggestions about the circumstances inwhich
sensitivity analyses should be presented are men-
tioned throughout the tutorial series and also in the
reviewer’s checklist.20
PRESENTATION OF THE EVIDENCE, RESULTS,
AND METHODS OF EVIDENCE SYNTHESIS
There is a need to present the input data for the
CEA, the summary statistics of the parameters used
in it, and the incremental costs and effects. The
2008 methods guide gives little detail on how to do
this, but we suggest that when there are more than 2
treatments in the comparator set for synthesis, it is
helpful to show a network diagram (such as Figure
2). Software for automatically drawing such diagrams
is available as stand-alone programs with multiple
capabilities (e.g., Pajek23) or as packages and routines
developed for R24 among other programs.
Further refinements in network diagrams that can
be implemented in various software include 1) add-
ing the number of studies making that comparison
to each connecting line (Figure 3) and 2) having the
thickness of the connecting lines reflect the number
of trials on that contrast and the size of the vertices
reflect the number of patients randomized to that
treatment.25 A second useful presentation of the
data is as a table of the sort shown here in Table 2.
It is also convenient to add columns indicating tri-
al-level covariate values orwhether IPD are available.
Similarly, in the interests of transparency,
reviewers and general readers must be provided
with sufficient information to allow them to repro-
duce the analyses, if they had access to the data. If
possible, journal citations for the precise model of
the data being assumed, and/or citation of the source
of software code, must be provided. Otherwise the
statistical model for the synthesis should be set out
fully in algebraic form and the software code used
for the synthesis should be annotated andmade avail-
able, along with the data used. When confidentiality
requirements prevent the data from being released,
a dummy data set with the same structure as the orig-
inal should be provided.
A clear discussion of the underlying statistical and
clinical assumptions implied by the model, and their
impact on the final decision, should also be included.
In particular, reasons for choosing to model the out-
comes on a particular scale (e.g., odds ratio, hazard
ratio, risk difference etc.) and the assumptions
implied in any transformation from the relative to
Cabergoline
(5)
Placebo
(1)
Ropinirole
(3)
Bromocripne
(4)
Pramipexole
(2)
2
1
1
2
1
2
Figure 3 Parkinson network.34 Each edge represents a treatment,
and connecting lines indicate pairs of treatments that have been
directly compared in randomized trials. The numbers on the lines
indicate the numbers of trials making that comparison, and the
numbers in brackets represent the treatment coding used in the
analysis.
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the absolute effects should be clearly presented.10,18
Transparency also requires that the choice of statisti-
calmodel (e.g., fixed or random effects) and the use of
anNMA, bias adjustment, ormeta-regression be justi-
fied on statistical and/or clinical grounds.10-12
Although the parameters required by the CEA tend
to be the absolute treatment effects of each treat-
ment,18 it is essential to present both the relative
treatment effects, which are the outputs from the evi-
dence synthesis, and the absolute effects on which
the CEA is based. It is important for those reviewing
and evaluating submissions that there is absolute
clarity and transparency about exactly what relative
efficacies between treatments are being assumed
and exactly what absolute effects are going forward
into the CEA. This can be achieved in a number of
ways. Perhaps the simplest method is a table of the
mean treatment effect with 95% credible interval
(CrI) of every treatment relative to placebo or to a stan-
dard comparator. Table 3 gives an example of the rel-
ative and absolute mean lost work-time reduction in
patients given 4 dopamine agonists and placebo as
adjunct therapy for Parkinson’s disease.10 The treat-
ment network is presented in Figure 3.
Another format (Table 4) allows investigators to
contrast results of pairwise meta-analyses with the
results of the NMA. Although this table does not con-
stitute a formal analysis of inconsistency in the net-
work,12 if the direct estimates are very close to their
network counterparts, there may be no need to pro-
ceed with further consideration of inconsistency.
Similarly, graphical displays that summarize the
results in the tables can be presented (Figure 4). The
draft of the 2013 methods guide4 also emphasizes
the use of forest plots to examine agreement between
the direct and indirect estimates of treatment effects,
which could be generated through node-splitting
methods.26
A number of authors tabulate the probability that
each treatment is most effective, which is an output
available from Bayesian or other simulation-based
approaches. This should be treated with great cau-
tion, particularly when there are many treatment
alternatives. A treatment whose mean effect ranks
quite low may still have a high probability of being
best if there is relatively more uncertainty in its
mean effect. This is misleading because for a given
set of expected (mean) treatment effects, greater
uncertainty may flatter a treatment. Differences
between treatments in probability of being best of
less than 90% cannot be given much credence. A
more reliable indicator is a plot of the rankings of
each treatment, or ‘‘rankograms.’’ When there are
multiple outcomes (e.g., remission, relapse, discon-
tinuation due to side effects), separate rankograms
for each treatment, plotting the ranks on each out-
come, can be very informative.27,28 Other graphical
presentations of results that are useful in different cir-
cumstances have been suggested.29
CONCLUSION
As far as we know, an overall account of evidence
synthesis has not been attempted before. In this series
Table 2 Certolizumab Pegol (CZP) for Rheumatoid Arthritis
Study Namea Placebo CZP Adalimumab Etanercept Infliximab Rituximab Tocilizumab Mean Disease Duration (Years)
Kim 2007 9/63 28/65 6.85
DE019 19/200 81/207 10.95
ARMADA 5/62 37/67 11.65
RAPID 1 15/199 146/393 6.15
RAPID 2 4/127 80/246 5.85
START 33/363 110/360 8.1
ATTEST 22/110 61/165 7.85
Abe 2006b 0/47 15/49 8.3
Weinblatt 1999 1/30 23/59 13
Strand 2006 5/40 5/40 11.25
CHARISMAb 14/49 26/50 0.915
OPTION 22/204 90/205 7.65
Note: Number of patients achieving ACR50 at 6 months, out of the total number of patients, in 12 trials comparing 6 treatments with placebo, and mean
disease duration (in years) for patients in each trial. Blank cells indicate that the treatment was not compared in that trial. All trial arms had methotrexate
in addition to the placebo or active treatment.
a. For study references, see Reference 37 in this article.
b. ACR50 at 3 months.
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of papers we present a single framework that covers
fixed and random effects models, in which pairwise
meta-analysis, indirect comparisons, and 2-arm tri-
als are special cases of networks, and indeed of mul-
tiarm trials, and in which outcomes expressed in
several different reporting formats can be analyzed
without recourse to normal approximations that
are known to be problematic.30 Although the tutori-
als in this series conform to a set of principles and
requirements originating from NICE’s decision-
making process, many of these principles—account-
ability, fairness, transparency—are desirable in all
evidence synthesis and decision-making settings.
Therefore, we hope that these papers will be useful
for a far wider community in medical decision
making.
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Table 3 Parkinson’s Example34: Posterior Mean (x), Standard Deviation (s), and 95% Credible Interval (CrI)
of the Mean Lost Work-Time Reduction for the Fixed Effects Models for the Treatment Effects Relative to
Placebo, and Absolute Mean Lost Work-Time Reduction for Placebo and All Treatments
Relative Effects of Treatment Y Compared with X
X Y x s 95% CrI
Placebo Pramipexole 21.81 0.33 22.46, 21.16
Placebo Ropinirole 20.47 0.49 21.43, 0.49
Placebo Bromocriptine 20.52 0.48 21.46, 0.43
Placebo Cabergoline 20.82 0.52 21.84, 0.22
Absolute Treatment Effects
x s 95% CrI
Placebo 20.73 0.22 21.16, 20.30
Pramipexole 22.54 0.40 23.32, 21.76
Ropinirole 21.21 0.53 22.25, 20.15
Bromocriptine 21.25 0.53 22.28, 20.21
Cabergoline 21.55 0.57 22.66, 20.43
Table 4 Parkinson’s example34: Posterior Mean (x), Standard Deviation (s), and 95% Credible Interval (CrI)
of the Relative Effect of Treatment Y Compared with X for All Possible Treatment Comparisons, for the
Network Meta-analysis and Separate Pairwise Meta-analyses with Fixed Effects
Network Meta-analysis Pairwise Meta-analyses
X Y x s 95% CrI x s 95% CrI
Placebo Pramipexole 21.81 0.33 22.46, 21.16 21.83 0.34 22.49, 21.17
Placebo Ropinirole 20.47 0.49 21.43, 0.49 20.31 0.67 21.62, 1.00
Placebo Bromocriptine 20.52 0.48 21.46, 0.43 20.90 0.69 22.26, 0.46
Placebo Cabergoline 20.82 0.52 21.84, 0.22 — — —
Pramipexole Ropinirole 1.34 0.54 0.28, 2.41 — — —
Pramipexole Bromocriptine 1.29 0.52 0.27, 2.32 1.40 0.70 0.03, 2.77
Pramipexole Cabergoline 0.99 0.56 20.10, 2.10 — — —
Ropinirole Bromocriptine 20.04 0.32 20.68, 0.59 0.00 0.35 20.68, 0.68
Ropinirole Cabergoline 20.34 0.38 21.10, 0.41 — — —
Bromocriptine Cabergoline 20.30 0.21 20.71, 0.11 20.30 0.21 20.71, 0.11
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